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Background/aim: Autoimmune thyroid disease in women is associated with subfertility and early pregnancy loss, and patients with
primary ovarian insufficiency have a high prevalence of thyroid autoimmune disorders. The aim of this study was to investigate the
association between Hashimoto thyroiditis (HT) and ovarian reserve.
Materials and methods: Levels of serum thyroid stimulating hormones, thyroid autoantibodies, and anti-Müllerian hormone (AMH)
were measured in women with HT and a healthy control group between 2018 and 2019.
Results: Evaluation was made of 108 premenopausal women with HT, and a control group of 172 healthy females with normal antithyroid
antibody levels and thyroid function. Serum AMH levels were determined to be significantly lower in the HT group compared to the
control group.
Conclusion: Ovarian reserve evaluated by serum AMH concentration is affected by thyroid autoimmunity independently of antithyroid
antibodies type or titers.
Key words: Hashimoto thyroiditis, anti-Müllerian hormone, ovarian reserve, miscarriage

1. Introduction
In women of reproductive age, thyroid dysfunction is
the most common endocrine disorder and the most
prevalent cause is thyroid autoimmunity [1]. Thyroid
peroxidase antibodies (TPOAb) are present in almost
90% of Hashimoto thyroiditis (HT) cases. In reproductive
age women, the prevalence of TPOAb is 8%–14% [2].
Antithyroglobuline antibodies (TgAb) are found in 70% of
patients with HT. Thyroid autoimmune disease prevalence
varies between 5% and 15% in women of reproductive
age [3]. The reproductive system is directly affected by
thyroid dysfunction as oocytes are affected through
thyroid hormone receptors on the surface of these cells
[4], and there is an indirect effect through the increased
prolactin secretion and disrupted GnRH function [5,6]. It
has also been reported that thyroid autoimmune disease
may be associated with general autoimmunity, resulting in
premature ovarian failure. Nevertheless, there has still not
been full clarification of the main pathophysiology linking
ovarian reserves with TPOAband thyroid hormones [6,7].

The complex clinical phenomenon of ovarian reserve is
influenced by age, genetics, and environmental variables.
Biochemical basal and provocative tests and ultrasound
imaging of the ovaries are used in ovarian reserve tests.
In current clinical practice, the markers most often used
are basal follicle stimulating hormone (FSH) levels, antral
follicle count, and anti-Müllerian hormone (AMH)
[8]. AMH is produced by the granulosa cells of ovarian
antral follicles. It indicates both the number of follicles
in the follicle pool, and early antral follicles. As age
increases, AMH production decreases, so it may be used
for evaluation of the ovarian reserve [1,2,9]. As AMH is
relatively stable throughout the menstrual cycle in normoovulatory women there is no advantage to assessment
made by measuring the hormone on a specific day of the
menstrual cycle. General guidelines have reported the
5-year age group classifications of the lower limits of ageappropriate serum AMH values as: 0.5 ng/mL at 45 years,
1 ng/mL at 40 years, 1.5 ng/ mL at 35 years, 2.5 ng/mL at
30 years, and 3.0 ng/mL at 25 years [8].

* Correspondence: ilknur_dr@yahoo.com

716

This work is licensed under a Creative Commons Attribution 4.0 International License.

ÖZTÜRK ÜNSAL et al. / Turk J Med Sci
Previous studies have shown that thyroid autoimmune
disorders have been detected in 12%–33% of patients with
premature ovarian failure [10]. Therefore, infertile patients
with autoimmune thyroid diseases may have decreased
ovarian reserves. In this case, if thyroid autoimmunity has
an effect on follicular growth and development, it may also
affect AMH concentrations, independently of female age.
The aim of this study was to investigate the correlation
between thyroid status, thyroid autoantibodies, and AMH
levels in reproductive-aged women.
2. Materials and methods
2.1. Study population
This retrospective case-control study included a total of
108 patients with euthyroid HT, with regular menstrual
cycles ofbetween 25 and 35 days, both those using and not
using levothyroxine, and 172 age-matched healthy female
volunteers. Patients were excluded if they were aged <18
years or >40 years, had a history of autoimmune disease or
polycystic ovary syndrome, or weere taking any adjuvant
treatment such as glucocorticoids or anticoagulants.
The control group was formed of 172 healthy, euthyroid
women with regular ovulatory cycles. The study was
conducted in the Endocrinology Department of Dışkapı
Yıldırım Beyazıt Training and Research Hospital between
January 2018 and December 2019. Demographic data
were collected together with clinical details and laboratory
values.
2.2. Clinical, biochemical, and hormonal evaluation
Baseline demographic data, clinical characteristics
(pregnancy and menstrual cycle history), duration of
hypothyroidism, and medications were recorded for all
study subjects. Hormonal assays measured in the early
follicular phase included serum AMH, free thyroxine
(fT4), thyroid stimulating hormone (TSH), thyroid
autoantibodies, follicle stimulating hormone (FSH),
luteinizing hormone (LH), estradiol (E2), and prolactin
(PRL). Blood samples were taken from all patients
between 8:00 am and 11:00 am after a 10-hr overnight fast.
The serum AMH concentrations were determined fully
automated by electrochemiluminescence immunoassay
(ECLIA) (Elecsys Cobas e 411-601-602, Roche Diagnostic,
Basel, Switzerland, catalog number 0631076 190). AMH
levels <1.00 ng/mL were accepted as low. Serum fT4, TSH,
TPOAb, and TgAb concentrations, FSH, LH, E2 and PRL
levels were measured using ACCEESS 2 immunoassay
system (Beckman Coulter, Brea, CA, USA, catalog number
81600N, serial number 509248 and 50992) (reference
ranges: fT4, 0.82–1.6 ng/dL; TSH, 0.38–5.33 mIU/L;
prolactin, 3.34–26.72 ng/mL). The reference range for
TPOAb and TgAb was 0–9and 0–4 IU/mL, respectively
at our hospital.

2.3. Statistical analysis
Statistical analyses were performed using IBM SPSS
Statistics for Windows, version 21.0 software (IBM Corp.,
Armonk, NY, USA). The variables were investigated
using visual (histograms, probability plots) and analytical
methods (Kolmogorov–Smirnov/Shapiro–Wilk tests)
to assess conformity to normal distribution. The Mann–
Whitney U test was performed to compare age, abortus,
TSH, fT4, TPOAb and TgAb levels and positivity rates,
FSH, LH, estradiol, prolactin, and AMH levels. The
Mann–Whitney U test was applied in the comparisons of
the AMH levels of the patients classified according to the
number of positive thyroid autoantibodies. Descriptive
analyses were presented using median values and the
interquartile range (IQR) of the 25th and 75th percentiles
for nonnormally distributed variables. A p-value <0.05
was accepted as a statistically significant difference. An
overall 5% type-1 error level was used to infer statistical
significance. While investigating the associations between
AMH level and other variables, correlation coefficients and
their significance were calculated using the Spearman test.
Multivariate logistic regression analysis was performed to
determine independent predictors of a low AMH level.
The relation between categorical variables were analyzed
using chi-square test.
3. Results
Evaluation was made of 108 patients with HT with a
median age of 32 years (IQR; 27.3–38) and 172 control
subjects with a median age of 31 years (IQR; 25–37)
(p = 0.209). Of the HT patients, 38.9% (42/108) were
using levothyroxine. The median disease duration of the
patients was 4 years (IQR; 1.9–6.3). The majority of the
study subjects had a history of at least one pregnancy, and
miscarriage was reported in 8 (7.4%) HT patients and 4
(2.3%) of the control group (p = 0.041).The median TSH
level was 3.1 mIU/L (IQR; 1.5–4.6) in the HT patient group
and 2.1 mIU/L (IQR; 1.4–2.9) in the control group. The
TSH levels of the patients were found to be significantly
higher than those of the control group (p = 0.001). The fT4
levels were similar in both groups (p = 0.497). The median
TSH was determined as 2.8 mIU/L (IQR 25–75; 1.56–4.65)
in patients with euthyroid HT who were not receiving
levothyroxine replacement.
The median TPOAb level of the patient group was 102
(94.4%) IU/mL and TgAb level was 46 (45.1%) IU/mL.
The TPOAb and TgAb levels of the patient group were
significantly higher than those of the control group (p <
0.001 for each). The FSH, LH, estradiol, and prolactin levels
of the patients were similar to those of the control subjects
(p = 0.684, p = 0.854, p = 0.064, p = 0.162; respectively).
The median AMH level was 1.53 ng/mL (IQR; 0.77–3.6)
in the HT group and 2.3 ng/mL (IQR; 1.1–3.8) in the
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control group. AMH levels were found to be lower in the
HT patients compared to the control group (p = 0.047)
(Figure). AMH levels in 35.2% (n = 38) of HT patients and
in 23.8% (n = 41) of the control group were determined
to be <1 ng/mL (p = 0.04). The baseline data, laboratory
parameters, and AMH levels are presented in Table 1.
The AMH level was found to be negatively correlated
with age (r = –0.489, p =< 0.001). There was no relation
between AMH level and TSH, fT4, TPOAb and TgAb
levels, and disease duration (Table 2). In the multivariate
logistic regression analysis, only age (OR: 0.738, 95% CI:
0.595–0.916, p = 0.005) was found to be an independent
risk factor for low AMH level in patients with euthyroid HT.
No significant difference in AMH levels was determined
between subjects who had or had not had a miscarriage
and those who were using or not using levothyroxine (p
= 0.366, p = 0.734; respectively). There was no difference
in AMH levels between patients who had one (either TPO
antibody or Tg antibody) or two (both TPO antibody
and Tg antibody) positive thyroid autoantibodies (p =
0.543). No significant difference was determined in AMH
levels between HT patients who were TPOAb(+) and
TgAb(–) vs. TPOAb(–) and TgAb(+) (p = 0.163, p = 0.992;
respectively). The number of patients with AMH level <1
ng/mL was similar in the subgroups according to TPOAb
or TgAb positivity (p = 0.098, p = 0.744; respectively).
4. Discussion
The main finding of this study was lower AMH levels were
determined in women with HT than in the age-matched
healthy women. No correlations were found between
AMH level and TSH, fT4, TPOAb and TgAb levels, and

disease duration. Menstrual regularity and ovarian reserve
play a critical role in achieving pregnancy in reproductiveage women. Premature ovarian failure (POF) is gonadal
failure defined by clinical and laboratory findings before
the age of 40. AMH is accepted as a reliable marker for
the quantitative evaluation of ovarian reserve, and serum
AMH concentration varies with ageing of the female [11].
Ovarian expression of AMH starts in fetal life, reaches a
peak at puberty, starts to decline in adulthood and does not
occur after menopause. In women with normal menstrual
cycles, levels of serum AMH have been shown to decrease
before FSH rises [12].
Cellular immunity and autoimmune process
abnormalities play a role in the autoimmune etiology of
POF. There has been stated to be a personal or family history
of autoimmune diseasein 80% of females with idiopathic
POF, high titers of thyroid autoantibodies in 50%, and
antiovary antibodies in 20%. HT is the most frequently
seen disease accompanying POF in adult women [13–16].
The hypothesis of this study was that thyroid autoimmunity
may suppress follicle development and would therefore
reduce the ovarian reserve in patients with HT. It was
assumed that when antithyroid antibodies are present, they
may cause antibody-mediated cytotoxicity in the growing
ovarian follicle and damage to the maturing oocyte,
thereby leading to diminished quality and developmental
potential. In the hypothesis of cross-reactivity, it has been
suggested that thyroid autoantibodies alter fertility by
targeting zonapellucida, human chorionic gonadotropin
receptors and other placental antigens [17]. Weghofer et
al. reported thyroid autoimmunity at the rate of 11.1%
and serum AMH concentration was 1.3 ± 2.0 ng/mL in

Figure. The graphs of anti-Müllerian hormone levels of the groups.
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Table 1. Baseline data and laboratory parameters belonging to Hashimoto thyroiditis patients and controls.
Hashimoto patients

Controls

p value

Number,n

108

172

Age, years

32 (27.3–38)

31 (25–37)

LT4 usage, n (%)

42 (38.9)

-

-

Disease duration, years

4 (1.9–6.3)

-

-

Patients with miscarriage, n (%)

8 (7.4)

4 (2.3)

0.041

Abortion number, n (%)

1 (1–1)

1 (1–2)

0.642

0.209

TSH (mIU/L)

3.1 (1.5–4.6)

2.1 (1.4–2.9)

0.001

fT4(ng/dL)

0.95 (0.83–1.1)

0.93 (0.8–1.1)

0.497

TPOAb(IU/mL)

195 (72–402)

0.7 (0.4–1.1)

<0.001

TPOAb positivity, n (%)

102 (94.4)

0 (0)

-

TgAb (IU/mL)

92.2 (0.9–158)

0.9 (0.9–0.9)

<0.001

TgAb, positivity, n (%)

46 (45.1)

0 (0)

-

FSH (IU/L)

4.3 (6.1–8.1)

6 (4.1–8)

0.684

LH (IU/L)

5.3 (3.2–7.4)

4.8 (3.3–7.3)

0.854

Estradiol (ng/L)

75 (45–106)

54 (36–99.9)

0.064

Prolactin (ng/mL)

11.6 (8.6–14.5)

12 (9–16.6)

0.162

AMH (ng/mL)

1.53 (0.77–3.6)

2.3 (1.1–3.8)

0.047

AMH<1 ng/mL subjects, n (%)

38 (35.2)

41 (23.8)

0.04

Categorical data demonstrated with numbers and percentages (%). Other variables were presented as
medians (interquartile ranges 25–75).
Table 2. Correlation analysis results of AMH levels and other
parameters.
R

p value

Age

–0.489

<0.001

Disease duration

–0.055

0.729

TSH level

0.023

0.700

fT4 level

0.016

0.796

TPOAb level

–0.084

0.173

TgAb level

–0.047

0.471

225 women who underwent IVF. In that study, the mean
AMH levels were determined to be significantly higher in
women with TSH <3.0 μIU/mL compared to those with
TSH ≥3.0 μIU/mL (p = 0.02) [1]. It was concluded that
there was robust statistical evidence that thyroid function
in the euthyroid range has a more significant role in the
effect on the ovarian reserve than thyroid autoimmunity.
However, in the current study, median TSH was 2.8 mIU/L

(IQR 25–75;1.56–4.65) in patients with HT who did not
use levothyroxine. In the 2012 American Association of
Clinical Endocrinologists (AACE) and America Thyroid
Association (ATA) cosponsored guidelines, it is stated
that the upper limit of a third generation TSH should
be considered as 4.12 mIU/L in iodine-sufficient areas.
Morover, approximately 20%–26% of the population could
be considered hypothyroid if the upper limit of the normal
range were decreased to 2.5–3.0 mIU/L [18].
Kurado et al. showed that AMH levels in women with
Hashimoto’s thyroiditis were improved with LT4 treatment,
but there was no correlation between thyroid antibody
titers and serum AMH levels during LT4 supplementation
[19]. In contrast in the current study, no differences were
determined in serum AMH concentrations of HT patients
using or not using levothyroxine (p = 0.734). In a study
of euthyroid HT adolescents, Pirgon et al. demonstrated
that AMH levels were significantly higher in the HT group
than in the control group [17]. In another study, serum
AMH levels were determined to be significantly higher
in women with HT than in the control group [12]. These
results suggested that there could be a common etiological
link in HT and polycystic ovary syndrome (PCOS),
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therefore PCOS patients were not included in the current
study.
As expected, there was determined to be a negative
correlation between serum AMH levels and age in this
study (r= –0.489, p =< 0.001). However, there was no
significant correlation of AMH concentration with the
levels of TgAb or TPOAb and TSH. Similarly, Chen et al.
demonstrated a relationship between positive TPOAb and
idiopathic low ovarian reserve in Chinese women, but this
was not related to TPOAb levels [20]. Osuka et al. reported
that thyroid autoantibodies are not likely to affect ovarian
reserve in euthyroid women with a TSH level within the
normal range, but elevated TSH levels may be involved in
decreasing serum AMH levels [11]. Saglam et al. reported
lower AMH levels in euthyroid women with HT compared
to an age- and BMI-matched healthy control group (1.16
± 0.17 vs. 1.28 ± 0.25, p = 0.001 [21]. The results of the
current study demonstrated that statistically significantly
more HT patients had AMH concentration <1 ng/mL
compared to the control group (35.2% vs. 23.8%; p = 0.04).
Several studies have shown a correlation between
subclinical hypothyroidisim and adverse pregnancy
outcomes. The results of a metaanalysis showed that the
prevalence of miscarriage in patients with subclinical
hypothyroidism with autoimmune thyroiditis was
significantly higher compared to those with subclinical
hypothyroidism only. However, the effect of subclinical
hypothyroidism on the risk of miscarriage is unclear.
In this study, the rate of miscarriage in patients with
HT was statistically significantly higher than in control
subjects (p = 0.041), but there was no difference in AMH
levels between those with or without a miscarriage (p
= 0.366). This suggests that autoimmunity itself may
increase the risk of miscarriage. Glinoer et al. reported
that thyroid autoantibodies indicate abnormal immune
function, which induces miscarriage by unstable placenta
implantation [22]. This was explained with 3 hypotheses:
The first stated that pregnancy loss is not directly
linked to the presence of circulating thyroid antibodies,
but rather to a more general autoimmune imbalance,
which would therefore explain the higher rejection rate
of fetal graft. In the second hypothesis, it is assumed
that even if there is apparent euthyroidism, the presence
of autoimmune thyroid disease could be related tothe
decreased thyroid function capacity to adapt sufficiently to
the changes of pregnancy with a reduced functional reserve
of the thyroid gland. The third hypothesis stated that there
was a tendency for pregnancy at an older age in thyroid
autoantibody positive women and older women are more
prone to pregnancy loss [23]. However, further studies on
this matter may be needed to reveal the mechanisms.
There were some limitations to this study, primarily the
retrospective design and that antral follicle count could
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not be evaluated. Most studies of thyroid autoimmunity
and ovarian reserve have been conducted on infertile
women. This study can be considered to contribute to
the limited available literature on ovarian reserve in
patients with autoimmune thyroiditis. There have been
previous studies in literature examining autoimmune
thyroid disease and AMH levels in infertile patients using
levothyroxine supplementation. Although the current
study also evaluated AMH concentrations in women with
euthyroid HT, the patients in this study had not presented
because of infertility.
5. Conclusion
We observed significant difference for serum AMH levels
between healthy women and women suffering from HT.
Age is independent risk factor in the decline of serum
AMH levels in adult women with autoimmune thyroiditis,
and these women must be followed up for premature
ovarian failure and infertility. The relationships between
autoimmune thyroid disease and reproductive failure have
been investigated in numerous studies of infertile women.
Nevertheless, due to the difficulties in interpreting the
currently available data, there is a clear need for further
studies to more comprehensively examine the association
between ovarian reserve and HT.
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